GolfLogix joins Foresight Sports, Bushnell Golf and PinSeeker in Revelyst’s Golf Technology platform, a leading portfolio of golf technology brands

SAN DIEGO–(BUSINESS WIRE)–Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies, today announced the acquisition of GolfLogix, a leading golf course mapping company featuring the most expansive, detailed library of more than 40,000 courses worldwide, from 8AM Golf. The acquisition closed on July 9. Terms were not disclosed.

Founded in 1999, GolfLogix was the first company to introduce handheld GPS to the golf industry and has continued to innovate including releasing the first Golf GPS app in 2009, a revolutionary Puttbreaks feature in 2018 and now, the first 3D virtual reality offering in a Golf GPS app.

The GolfLogix business will be integrated into Revelyst’s Golf Technology platform, which recently announced a rebranding. The addition of GolfLogix gives Revelyst’s San Diego-based platform another innovative brand in its growing portfolio, which includes Foresight Sports, Bushnell Golf and PinSeeker. This acquisition further expands the company’s product ecosystem, instantly increasing its software capabilities and on-course presence.

“We’re incredibly excited about this acquisition of GolfLogix,” said Eric Nyman, CEO of Revelyst. “This addition of a well-respected golf technology innovator strengthens our leadership in the golf tech space and opens the door to new categories where we see tremendous opportunity. By bringing GolfLogix onto Team Revelyst, we can accelerate our growth strategy and, more importantly, ensure that golfers of all levels have a one-stop shop for improving their game.”

Based in Scottsdale, Ariz., GolfLogix has been professionally mapping courses for nearly 25 years and owns the largest, most up-to-date golf course database in the world. Today, the company has a library of more than 40,000 golf courses mapped across the globe for use in the GolfLogix app, including its new, first of its kind 3D mapping features released in April 2025, its GreenBooks offering and through licensing. GolfLogix will maintain a presence in Scottsdale, which will become a digital studio for Revelyst Golf Technology in the future.

“This is a game-changing addition to our portfolio,” said Jeff Foster, GM and President of Revelyst Golf Technology. “It not only boosts our market presence but also gives us the tools to innovate in areas we’ve been eager to explore. We’re confident this will bring significant value to our customers and app users and fuel our next phase of growth.”

GolfLogix’s cofounders Scott Lambrecht and Pete Charleston said teaming up with Revelyst made the most sense as they look to begin the next chapter of their company. The new home will enable GolfLogix to double down on tech investment and reach scores of golf fans seeking to enhance their golf game through the world’s most innovative on- and off-course technology. Lambrecht and Charleston will remain with Revelyst post-acquisition.

“Joining forces with a leading golf tech company is an incredible opportunity for our team and our brand,” said Lambrecht, GolfLogix CEO. “We’re thrilled to bring our expertise into a larger ecosystem where we can reach more golfers and push innovation even further.”

Added Charleston, GolfLogix president: “This partnership allows us to scale in ways we couldn’t on our own. We’re excited to be part of a company that shares our passion for the game and is committed to delivering cutting-edge solutions for golfers everywhere.”

Reed Smith LLP served as legal adviser to Revelyst in connection with the transaction.

About GolfLogix

As the most frequently used app for golf, over 7 million golfers have downloaded GolfLogix on the world’s top-selling smartphones. GolfLogix has also created enhanced Green Books for over 15,000 courses worldwide. Dedicated to offering consumers the most advanced green mapping and GPS solutions with the most useful features at accessible prices, GolfLogix helps improve individual performance.

About Revelyst

Revelyst Inc. is a collective of world-class maker brands that design and manufacture performance gear and precision technologies. Our category-defining brands leverage meticulous craftsmanship and cross-collaboration to pursue new innovations that redefine what is humanly possible in the outdoors. Portfolio brands include Foresight Sports, Bushnell Golf, Fox, Bell, Giro, CamelBak, Bushnell, Simms Fishing and more. For more information, visit our website at www.revelyst.com.

When Whoop introduced its new hardware and membership tiers back in May, one of the devices was called the MG, with the abbreviation standing for “Medical Grade.” Among the big features ostensibly making it worth the upgrade was something called Blood Pressure Insights. But now the FDA has sent Whoop a warning letter saying that Whoop is marketing an unapproved medical device.

Whoop is a screenless fitness tracker with an extensive array of features that track a user’s fitness, sleep, and other metrics related to wellness. (You can read about my experiences tracking my health with Whoop here.)

In a message to members posted today on the r/Whoop subreddit, Whoop stated that, despite the FDA letter, the Blood Pressure Insights feature “remains available” to members on the Life tier. This is the highest tier of membership and the only one that was marketed as including Blood Pressure Insights. Whoop also stated that any regulatory issues with the FDA don’t affect devices sold outside the U.S.

If you have a Whoop 4.0 or 5.0, this doesn’t apply to you either; the issue is solely about the blood pressure feature offered in the top-tier Life membership ($359/year) with the MG (“medical grade”) device. 

Why the FDA intervened (and how Whoop responded)

According to the FDA’s letter, measuring and reporting users’ blood pressure classifies the Blood Pressure Insights feature as a medical device. Medical devices that can measure blood pressure need to be approved by the FDA before they go to market. 

Note that the FDA’s letter is directed at the Blood Pressure Insights feature, not the Whoop MG hardware itself. Whoop argued (to the FDA, according to the letter) that the blood pressure feature falls under the definition of software that is intended for “maintaining or encouraging a healthy lifestyle,” and thus is exempt from the rules for medical devices. 

The FDA counters that the measurement of blood pressure is “inherently associated with the diagnosis of hypo- and hypertension, and is therefore intended for use in the diagnosis of a disease or other condition, or in the cure, mitigation, treatment, or prevention of disease.” The FDA notes that they have approved other blood pressure monitors that didn’t make direct claims about disease, and they consider Whoop’s blood pressure readings to be no different.

Whoop sees it differently, saying to members: “Wellness features like this are common in wearable technology without requiring FDA review, like tracking your respiratory rate or HRV, and provide valuable insights to support you in making better decisions. Blood pressure is no different.”

You can read the FDA’s entire warning letter here. It asks Whoop to reply with an explanation of how they will follow the rules going forward. You can also read Whoop’s notice to members here, where they explain why they believe they are not violating the law, and state that the Blood Pressure Insights feature remains available. 

What this could mean for Whoop

To be fair, Whoop was perhaps sticking its neck out a bit by offering an MG (“medical grade”) edition of its wristband. The standard model, without the blood pressure feature, is the Whoop 5.0, which provides the company’s established fitness and wellness metrics for either $199/year (the “One” membership) or $239/year (the “Peak” membership). But the Whoop MG is an upgraded version that goes with the “Life” membership for $359/year. 

What does that significant price hike buy you? Three features, according to Whoop’s pricing page, and two of those are “medically regulated,” in Whoop’s words: ECG readings and irregular heart rhythm notifications. Both of these can tell you if there are problems with the rhythm of your heartbeat. According to Whoop’s country-by-country availability page, ECG readings are available in 39 countries, including the U.S. This feature requires you to put your fingers on the device’s metal clasp and leave them there while it takes a reading.

Irregular heart rhythm notifications, meanwhile, are available in 36 countries, but the U.S. is not one of them.

Blood pressure is the third feature (or, if you’re in the U.S., the second) that the Life membership buys you. Which means that if Whoop ends up having to pull it, you’re essentially paying an extra $120 each year for the ability to take ECG readings—a pretty standard feature on smartwatches these days. Heck, you can buy an entire Apple Watch SE for $169, and it has an ECG app. (It also will last more than a year.) So if the company has to stop offering Blood Pressure Insights, the expensive subscription doesn’t make much sense. 

“Since this is one of the selling points of Life I’m hoping there’s going to be compensation if this feature will be removed, we paid for it,” said one Redditor in a reply to Whoop’s statement. So far, the feature is still available—presumably while Whoop continues to argue its side to the FDA.

07/15/2025 – 09:17 AM

AI-Powered Emotion Scanner Aims to Revolutionize Mental Health Screening Across Telehealth, Education & Consumer Platforms

MESA, ARIZONA / ACCESS Newswire / July 15, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a health-tech innovator pushing the boundaries of AI-powered diagnostics, today announces a major advancement in its digital health portfolio: an AI Facial Micro-Expression Mental Health Scanner designed to detect early emotional and psychological distress using nothing more than a short selfie video.

This next-gen technology merges facial coding with affective computing, decoding subtle micro-expressions that often precede visible symptoms of depression, anxiety, or PTSD. By identifying these emotional biomarkers before patients even recognize the signs themselves, MDCE is laying the groundwork for real-time, scalable, preventive mental health screening.

“This technology has the potential to redefine how mental health is approached globally,” said a company spokesperson. “With integration pathways ranging from telehealth to university counseling centers to wearable platforms, we are targeting a market that is not only underserved, but urgently in need of scalable, stigma-free solutions.”

The global mental health tech market is projected to exceed $60 billion by 2030, and MDCE’s innovation is positioned at the intersection of artificial intelligence, digital therapeutics, and mass accessibility. By enabling frictionless, non-invasive screening via smartphones and connected devices, the company believes this solution could transform both early detection and long-term outcomes for millions worldwide.

This initiative is part of MDCE’s expanding R&D focus, alongside its subsidiaries:

To learn more about the scanner or opportunities for early-stage collaboration, visit www.medicalcaretechnologies.com.

About Medical Care Technologies Inc. (OTC Pink: MDCE)

Medical Care Technologies Inc. is a forward-focused health tech company developing AI-based self-screening tools to empower users through early detection. With growing interest in AI diagnostic platforms, MDCE is developing solutions for wound care, dermatological monitoring, and mental health, targeting large and underserved markets.

Safe Harbor Statement

This press release contains forward-looking statements, including expectations for future product development and market impact. These statements involve risks and uncertainties. Actual results may differ. The company assumes no obligation to update these statements.

Company Info:
Medical Care Technologies Inc (OTC PINK:MDCE)
www.medicalcaretechnologies.com

Investor & Media Contact:
Infinite Auctions / MDCE
info@infiniteauctions.com

SOURCE: Medical Care Technologies Inc.

View the original press release on ACCESS Newswire

Elevate Your Investing Strategy:

Catapult Group International ( (AU:CAT) ) just unveiled an update.

Catapult Group International Ltd has announced a change in the director’s interest notice, involving Mr. James Ventura Orlando. The change includes the conversion of FY25 Director Fee Sacrifice Rights into fully paid ordinary shares and the acquisition of FY26 Director Fee Sacrifice Rights. This adjustment reflects the company’s ongoing commitment to aligning director interests with shareholder value, potentially impacting the company’s governance and stakeholder relations.

The most recent analyst rating on (AU:CAT) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Catapult Group International stock, see the AU:CAT Stock Forecast page.

More about Catapult Group International

Catapult Group International Ltd operates in the sports technology industry, providing performance analytics and wearable technology solutions primarily for sports teams and athletes. The company focuses on enhancing athletic performance and optimizing team management through data-driven insights.

Average Trading Volume: 1,379,572

Technical Sentiment Signal: Buy

Current Market Cap: A$1.61B

For an in-depth examination of CAT stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

AI-Powered Emotion Scanner Aims to Revolutionize Mental Health Screening Across Telehealth, Education & Consumer Platforms

MESA, ARIZONA / ACCESS Newswire / July 15, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a health-tech innovator pushing the boundaries of AI-powered diagnostics, today announces a major advancement in its digital health portfolio: an AI Facial Micro-Expression Mental Health Scanner designed to detect early emotional and psychological distress using nothing more than a short selfie video.

This next-gen technology merges facial coding with affective computing, decoding subtle micro-expressions that often precede visible symptoms of depression, anxiety, or PTSD. By identifying these emotional biomarkers before patients even recognize the signs themselves, MDCE is laying the groundwork for real-time, scalable, preventive mental health screening.

“This technology has the potential to redefine how mental health is approached globally,” said a company spokesperson. “With integration pathways ranging from telehealth to university counseling centers to wearable platforms, we are targeting a market that is not only underserved, but urgently in need of scalable, stigma-free solutions.”

The global mental health tech market is projected to exceed $60 billion by 2030, and MDCE’s innovation is positioned at the intersection of artificial intelligence, digital therapeutics, and mass accessibility. By enabling frictionless, non-invasive screening via smartphones and connected devices, the company believes this solution could transform both early detection and long-term outcomes for millions worldwide.

This initiative is part of MDCE’s expanding R&D focus, alongside its subsidiaries:

To learn more about the scanner or opportunities for early-stage collaboration, visit www.medicalcaretechnologies.com.

About Medical Care Technologies Inc. (OTC Pink: MDCE)

Medical Care Technologies Inc. is a forward-focused health tech company developing AI-based self-screening tools to empower users through early detection. With growing interest in AI diagnostic platforms, MDCE is developing solutions for wound care, dermatological monitoring, and mental health, targeting large and underserved markets.

Safe Harbor Statement

This press release contains forward-looking statements, including expectations for future product development and market impact. These statements involve risks and uncertainties. Actual results may differ. The company assumes no obligation to update these statements.

Company Info:
Medical Care Technologies Inc (OTC PINK:MDCE)
www.medicalcaretechnologies.com

Investor & Media Contact:
Infinite Auctions / MDCE
info@infiniteauctions.com

SOURCE: Medical Care Technologies Inc.

View the original press release on ACCESS Newswire

ACCESS Newswire

ACCESS Newswire is a newswire service that provides regional, national, and global news to thousands of clients worldwide. Its innovative technology paired with its expansive network of journalists and media outlets helps companies, both public and private, break through the noise of the market to share their stories and connect with their audiences.